Impact of graft-versus-host disease prophylaxis on second primary malignancies after allogeneic haematopoietic stem cell&#xa0;transplantation

Further Publications

Impact of graft-versus-host disease prophylaxis strategies on GvHD-free/relapse-free survival in young adults undergoing unrelated donor allogeneic haematopoietic cell transplantation: A propensity score-matched analysis

Br J Haematol

Desai N, Rodriguez SR, Al-Shaibani E, Moya TA, Novitzky-Basso I, Law AD

doi: 10.1111/bjh.70269

Leukemia

Graft-versus-host disease is not associated with reduced incidence of relapse following haploidentical stem cell transplantation with post-transplant cyclophosphamide for acute lymphoblastic leukaemia: A study on behalf of the Acute Leukaemia Working Party of European Society for Blood and Marrow Transplantation

Br J Haematol

Shimoni A, Peczynski C, Labopin M, Dominietto A, Koc M, Arat M, Tischer J, Sica S, Gülbas Z, Socié G, Blaise D, Pioltelli P, Ozdogu H, Vydra J, Ciceri F, Nagler A, Mohty M

doi: 10.1111/bjh.70101

Leukemia

Outcomes after a second allogeneic haematopoietic stem cell transplant for relapsed paediatric acute myeloid leukaemia improved over time: A study from the EBMT Paediatric Diseases Working Party

Br J Haematol

Buchbinder N, Michel V, Dalissier A, Kleinschmidt K, Locatelli F, Maschan A, Wynn R, Fagioli F, Zecca M, Jubert C, Versluys B, Sedlacek P, Zubarovskaya L, Gonzalez Vicent M, Biffi A, Michel G, Mirci-Danicar O, Holter W, Ansari M, Galimard JE, Schneider P, Abouqateb M, Kałwak K

doi: 10.1111/bjh.70167

Further Publications

Outcomes of children with haematological malignancies given second haploidentical haematopoietic stem cell transplantation with either TCRαβ/CD19 depletion or post-transplant cyclophosphamide

Br J Haematol

Masetti R, Leardini D, Gottardi F, Baccelli F, Ottaviano GAM, Vendemini F, Saglio F, Pierri F, Algeri M, Del Bufalo F, Merli P, Prete A, Cesaro S, Ussowicz M, Faraci M, Zecca M, Fagioli F, Balduzzi A, Dalle JH, Locatelli F, Pagliara D

doi: 10.1111/bjh.70004

Lymphoma

Treosulfan/fludarabine versus thiotepa/busulfan/fludarabine for allogeneic haematopoietic cell transplantation in lymphoma in the post-transplant cyclophosphamide era: A GETH-TC study

Br J Haematol

Peña M, Lazzari L, Martínez DF, Ciceri F, Balaguer-Roselló A, Sanz J, Pascual MJ, Benzaquén A, Piñana JL, Salas MQ, Nieto-Vazquez A, Español I, Huguet M, Bento L, Saez AJ, Barba P, Filaferro S, Carbonell Asins JA, Peña C, Mussetti A, Greco R

doi: 10.1111/bjh.70367

Lymphoma

Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy

J Clin Oncol

Stepan L, Ansari S, Abramson JS, Okal A, Dell'Aringa J, Thompson EG, Crotta A, Chow VA, Kamdar M, Solomon SR, Johnston PB, Glass B, Mutsaers P, Arnason J, Mielke S, Shadman M, Hernandez-Ilizaliturri F, Izutsu K, Bachanova V, Ibrahimi S, Chabon JJ, Kurtz DM, Alizadeh AA, Peiser L

doi: 10.1200/JCO-25-03051

Further Publications

Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial

Blood

Meyer E, Salhotra A, Gandhi A, Pantin J, Patel SS, Hoeg RT, Gomez-Arteaga A, Faramand RG, Tamari R, Waller EK, Kosuri S, Jimenez Jimenez AM, Holter-Chakrabarty J, Dholaria B, Chen YB, Hamilton BK, Magenau JM, Eghtedar A, Murray JM, Pavlova A, Fernhoff NB, McClellan JS, Killian S, Li A, Negrin RS, Oliai C

doi: 10.1182/blood.2025031313

Further Publications

Equivalent incidences of paediatric graft-versus-host disease regardless of donor-recipient matching in the era of modern prophylaxis agents

Br J Haematol

Ariagno S, Greenmyer J, Kuhn A, Pence L, O'Shea M, Greenmyer L, Cole K, Ferdjallah A, Kohorst M

doi: 10.1111/bjh.70184

Further Publications

Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease

J Clin Oncol

Cutler C, Kim HT, El Banna H, Halloran E, Matozel E, Ho VT, Koreth J, Gooptu M, Shapiro R, Kelkar A, Gibson C, Nikiforow S, Nageshwar P, Reynolds C, Ansuinelli M, Tamada R, Au C, Panaro K, Gervais C, DeFilipp Z, El-Jawahri A, Chen YB, El Jurdi N, Weisdorf D, Couriel D, Lee C, Arai S, Sahaf B, Bacigalupi J, Ji K, Soiffer R, Miklos D, Antin JH, Ritz J

doi: 10.1200/JCO-25-03104

Oncology · Hematology

Impact of graft-versus-host disease prophylaxis on second primary malignancies after allogeneic haematopoietic stem cell transplantation

Related content

Impact of graft-versus-host disease prophylaxis strategies on GvHD-free/relapse-free survival in young adults undergoing unrelated donor allogeneic haematopoietic cell transplantation: A propensity score-matched analysis

Outcomes after a second allogeneic haematopoietic stem cell transplant for relapsed paediatric acute myeloid leukaemia improved over time: A study from the EBMT Paediatric Diseases Working Party

Outcomes of children with haematological malignancies given second haploidentical haematopoietic stem cell transplantation with either TCRαβ/CD19 depletion or post-transplant cyclophosphamide

Treosulfan/fludarabine versus thiotepa/busulfan/fludarabine for allogeneic haematopoietic cell transplantation in lymphoma in the post-transplant cyclophosphamide era: A GETH-TC study

Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy

Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial

Equivalent incidences of paediatric graft-versus-host disease regardless of donor-recipient matching in the era of modern prophylaxis agents

Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease